Back to search

Article

Integration of ceritinib and bevacizumab as a promising treatment strategy for brain metastases from ALK mutation-position non-small cell lung cancer: a case report

2021-03-25

Abstract excerpt

Ceritinib shows efficacy in ALK+ NSCLC patients with BM. However, the disease will inevitably progress over time due to acquired resistance. We now report a case with BM from advanced lung adenocarcinoma with ALK mutations who exhibited a surprising and long-term response to treatment of ceritinib combined with bevacizumab.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f2b2c708-19ec-5775-87a1-2464c22c051d
DOI
10.22541/au.161671669.94056751/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Integration of ceritinib and bevacizumab as a promising treatment strategy for brain metastases from ALK mutation-position non-small cell lung cancer: a case reportDOI 10.22541/au.161671669.94056751/v1
A Clinical Research of Ceritinib Treating Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer With Brain MetastasisSemantic proximity
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.Semantic proximity
[Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review].Semantic proximity
Treatment of Alectinib in NSCLC with Brain Metastasis Patient Refractory to Radiotherapy after Resistance to Crizotinib: A Case Report and Literature ReviewSemantic proximity
Treatment Strategy of Lung Adenocarcinoma with Concomitant EGFR Mutation and ALK RearrangementSemantic proximity
Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.Semantic proximity
[Treatment of Patients with ALK-positive Non-small Cell Lung Cancer and Brain Metastases].Semantic proximity
Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.Semantic proximity
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.Semantic proximity
The Efficacy of EGFR-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Synchronous Brain Metastasis: A Real-World StudySemantic proximity
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity
Case Report: Durable disease stability in a patient with MET exon 14 skipping mutation and brain metastasis NSCLC following radiotherapy and immunotherapy.Semantic proximity
Select a neighboring publication to make it the new centre.